1/30
12:26 pm
insm
Insmed (NASDAQ:INSM) had its price target raised by analysts at Morgan Stanley from $157.00 to $162.00. They now have an "equal weight" rating on the stock.
Low
Report
Insmed (NASDAQ:INSM) had its price target raised by analysts at Morgan Stanley from $157.00 to $162.00. They now have an "equal weight" rating on the stock.
1/29
07:47 pm
insm
What Insmed (INSM)'s Upcoming TPIP Data and New Analyst Coverage Mean For Shareholders [Yahoo! Finance]
Low
Report
What Insmed (INSM)'s Upcoming TPIP Data and New Analyst Coverage Mean For Shareholders [Yahoo! Finance]
1/29
12:47 pm
insm
Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions [Yahoo! Finance]
Low
Report
Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions [Yahoo! Finance]
1/29
07:41 am
insm
Insmed (NASDAQ:INSM) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Insmed (NASDAQ:INSM) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/28
07:00 am
insm
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
Low
Report
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
1/27
06:00 pm
insm
Insmed (NASDAQ:INSM) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Medium
Report
Insmed (NASDAQ:INSM) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/24
06:29 am
insm
Insmed (NASDAQ:INSM) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.
Low
Report
Insmed (NASDAQ:INSM) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.
1/24
05:08 am
insm
Insmed (NASDAQ:INSM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Insmed (NASDAQ:INSM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/22
05:08 pm
insm
Insmed (NASDAQ:INSM) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.
Medium
Report
Insmed (NASDAQ:INSM) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.
1/22
10:00 am
insm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
1/21
07:17 am
insm
Insmed (NASDAQ:INSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Insmed (NASDAQ:INSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/20
04:07 pm
insm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
1/19
10:30 pm
insm
Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity [Seeking Alpha]
Low
Report
Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity [Seeking Alpha]
1/19
01:13 am
insm
Analyst Weighs Patent Cliff Risks Against Insmed's (INSM) Growth Story [Yahoo! Finance]
Low
Report
Analyst Weighs Patent Cliff Risks Against Insmed's (INSM) Growth Story [Yahoo! Finance]
1/15
10:00 am
insm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
1/13
04:27 pm
insm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
1/12
06:02 pm
insm
Insmed CEO Will Lewis talks its rare disease drug pipeline [CNBC]
Medium
Report
Insmed CEO Will Lewis talks its rare disease drug pipeline [CNBC]
1/12
01:05 pm
insm
Insmed (NASDAQ:INSM) was given a new $205.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Insmed (NASDAQ:INSM) was given a new $205.00 price target on by analysts at Truist Financial Corporation.
1/10
10:52 pm
insm
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? [Yahoo! Finance]
Medium
Report
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? [Yahoo! Finance]
1/10
07:02 pm
insm
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance Hike - Learn Why [Yahoo! Finance]
Medium
Report
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance Hike - Learn Why [Yahoo! Finance]
1/9
07:37 am
insm
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/9
07:00 am
insm
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/8
10:05 am
insm
Insmed (NASDAQ:INSM) was given a new $157.00 price target on by analysts at Morgan Stanley.
Low
Report
Insmed (NASDAQ:INSM) was given a new $157.00 price target on by analysts at Morgan Stanley.
1/8
10:00 am
insm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
1/8
07:31 am
insm
Jim Cramer on Insmed: “This One Is Worth Keeping an Eye On” [Yahoo! Finance]
Low
Report
Jim Cramer on Insmed: “This One Is Worth Keeping an Eye On” [Yahoo! Finance]